시장보고서
상품코드
1485042

원료의약품 CDMO 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 분자 유형별, 합성별, 약물 유형별, 워크플로우별, 용도별, 지역별, 지역별, 경쟁사별(2019-2029년)

Active Pharmaceutical Ingredients CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Molecule Type, By Synthesis, By Drug Type, By Workflow, By Application, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 182 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

원료의약품 CDMO 세계 시장 규모는 2023년 919억 8,000만 달러로 평가되었고, 2029년까지 연평균 6.10%의 꾸준한 성장세를 보일 것으로 예측됩니다.

제약업계는 원료의약품 생산과 의약품 애플리케이션 개발에 있어 많은 문제에 직면해 있습니다. 이러한 과제에는 고품질 기준을 유지하면서 비용을 절감해야 하는 필요성, 합리적인 가격의 장비에 대한 요구, 혁신적인 제품을 신속하게 시장에 출시해야 하는 압박 등이 포함됩니다. 이러한 도전에 대응하기 위해 CDMO(Contract Development and Manufacturing Organization)가 제약사의 중요한 파트너로 부상하고 있으며, CDMO는 제약사와 협력하여 인프라 및 자원에 대한 추가 투자없이 의약품을 개발 및 제조하는 역할을 수행합니다. CDMO에 원료의약품 제조를 아웃소싱함으로써 제약사는 연구 및 마케팅과 같은 핵심 역량에 집중할 수 있고, CDMO의 전문 지식과 역량을 제조 및 개발에 활용할 수 있습니다. 이러한 파트너십 모델을 통해 제약사는 신제품을 보다 빠르고 비용 효율적으로 시장에 출시할 수 있습니다. 제약 CDMO의 주요 역할 중 하나는 원료의약품의 아웃소싱입니다. CDMO는 전문 장비와 화학 및 제조 전문 지식을 활용하여 규제 표준을 충족하는 고품질 원료 의약품을 생산하기 위해 제약 회사가 제공 한 사양에 따라 원료 의약품(API) 및 의약품 중간체를 제조하는 것입니다.

시장 개요
예측 기간 2025-2029년
시장 규모 : 2023년 919억 8,000만 달러
시장 규모 : 2029년 1,307억 달러
CAGR : 2024-2029년 6.10%
급성장 부문 종양
최대 시장 북미

제약 CDMO는 원료의약품 생산 외에도 혁신과 개발 과정에서 중요한 역할을 담당하고 있으며, CDMO는 제조 전 단계에서 제약회사와 긴밀히 협력하여 제제 개발, 타당성 연구, 공정 최적화를 수행합니다. 이러한 협력을 통해 최종 제품이 유효성, 안전성 및 품질 측면에서 원하는 사양을 충족할 수 있도록 보장합니다. 제약회사와 CDMO의 파트너십은 상호 이익이 됩니다. 제약사는 CDMO의 최첨단 시설, 전문 지식, 확장 가능한 제조 능력을 활용하여 신약을 보다 신속하고 효율적으로 시장에 출시할 수 있는 이점을 누릴 수 있습니다. 반면 CDMO는 제약사와의 장기적인 파트너십을 통해 안정적인 비즈니스와 성장 기회를 얻을 수 있습니다. 제약 CDMO는 헬스케어 산업의 성장에 크게 기여하고 있습니다. CDMO는 제약사가 제조 및 개발 프로세스를 처리하면서 혁신과 신흥 시장에 집중할 수 있도록 함으로써 신약 개발 속도를 가속화하는 데 중요한 역할을 하고 있습니다. 그 결과, 미충족 의료 수요를 충족하고 환자의 치료 결과를 개선하는 새로운 치료법과 개선된 치료법을 도입할 수 있게 됩니다. 제약 CDMO는 원료 제조, 제형 개발, 공정 최적화 등 다양한 서비스를 제공하며, CDMO의 전문성과 역량을 활용함으로써 제약사들은 업무 효율을 높이고 비용을 절감하며 혁신적인 제품을 더 빨리 시장에 출시할 수 있습니다. 할 수 있습니다. 제약회사와 CDMO의 협력적 파트너십은 헬스케어 산업의 적극적인 성장을 가속하고 전 세계 환자들을 위한 새로운 치료법 개발을 촉진하는 데 필수적입니다.

주요 시장 성장 촉진요인

맞춤형 의약품 개발에 대한 수요 증가

바이오 의약품 분야의 성장

복잡한 약물 분자 증가

주요 시장 과제

규제의 복잡성

품질 관리 및 컴플라이언스

주요 시장 동향

세포치료와 유전자치료

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 원료의약품 CDMO 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 분자 유형별(소분자, 대분자)
    • 합성별(바이오테크놀러지, 합성)
    • 약제 유형별(혁신적 의약품, 제네릭 의약품)
    • 워크플로우별(임상, 상업)
    • 용도별(심장병학, 종양학, 안과, 신경학, 정형외과, 기타)
    • 지역별(북미, 유럽, 아시아태평양, 남미, 중동 및 아프리카)
    • 기업별(2023년)
  • 시장 맵
  • 분자 유형별
  • 합성별
  • 약제 유형별
  • 워크플로우별
  • 용도별
  • 지역별

제6장 북미의 원료의약품 CDMO 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 분자 유형별
    • 합성별
    • 약제 유형별
    • 워크플로우별
    • 용도별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 캐나다
    • 멕시코

제7장 유럽의 원료의약품 CDMO 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 분자 유형별
    • 합성별
    • 약제 유형별
    • 워크플로우별
    • 용도별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인

제8장 아시아태평양의 원료의약품 CDMO 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 분자 유형별
    • 합성별
    • 약제 유형별
    • 워크플로우별
    • 용도별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주

제9장 남미의 원료의약품 CDMO 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 분자 유형별
    • 합성별
    • 약제 유형별
    • 워크플로우별
    • 용도별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카의 원료의약품 CDMO 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 분자 유형별
    • 합성별
    • 약제 유형별
    • 워크플로우별
    • 용도별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 최근 동향
  • 인수합병(M&A)
  • 제품 출시

제13장 세계의 원료의약품 CDMO 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

  • 업계내 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제15장 경쟁 구도

  • Cambrex Corporation
  • Thermo Fisher Scientific, Inc.
  • Recipharm AB
  • Corden Pharma International GmbH
  • Samsung Biologics Co., Ltd.
  • Lonza Group Ltd.
  • Siegfried Holding AG
  • Piramal Pharma Limited
  • AbbVie Inc.
  • Catalent, Inc.

제16장 전략적 제안

제17장 리서치사에 대해 & 면책사항

LSH 24.06.04

Global Active Pharmaceutical Ingredients CDMO Market was valued at USD 91.98 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.10% through 2029. The pharmaceutical industry faces numerous challenges in the manufacturing of drug substances and the development of pharmaceutical applications. These challenges include the need to reduce costs while maintaining high-quality standards, the requirement for affordable equipment, and the pressure to bring innovative products to market quickly. In response to these challenges, Contract Development and Manufacturing Organizations (CDMOs) have emerged as key partners for pharmaceutical companies. CDMOs collaborate with pharmaceutical companies to develop and manufacture drugs without the need for additional investment in infrastructure or resources. By outsourcing drug substance manufacturing to CDMOs, pharmaceutical companies can focus on their core competencies such as research and marketing, while leveraging the expertise and capabilities of CDMOs in manufacturing and development. This partnership model allows pharmaceutical companies to bring new products to market faster and more cost-effectively. One of the primary roles of Pharmaceutical CDMOs is to handle the outsourcing of drug substances. This involves the production of active pharmaceutical ingredients (APIs) or drug intermediates according to the specifications provided by the pharmaceutical companies. CDMOs utilize their specialized facilities and expertise in chemistry and manufacturing to produce high-quality drug substances that meet regulatory standards.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 91.98 Billion
Market Size 2029USD 130.70 Billion
CAGR 2024-20296.10%
Fastest Growing SegmentOncology
Largest MarketNorth America

In addition to manufacturing drug substances, Pharmaceutical CDMOs also play a crucial role in the innovation and development process. CDMOs work closely with pharmaceutical companies during the pre-manufacturing phase to develop formulations, conduct feasibility studies, and optimize processes. This collaboration ensures that the final product meets the desired specifications in terms of efficacy, safety, and quality. The partnership between pharmaceutical companies and CDMOs is mutually beneficial. Pharmaceutical companies benefit from access to CDMO's state-of-the-art facilities, specialized expertise, and scalable manufacturing capabilities, allowing them to bring new drugs to market faster and more efficiently. On the other hand, CDMOs benefit from long-term partnerships with pharmaceutical companies, which provide a steady stream of business and opportunities for growth. Pharmaceutical CDMOs contribute significantly to the positive growth of the healthcare industry. By enabling pharmaceutical companies to focus on innovation and marketing while handling the manufacturing and development process, CDMOs play a vital role in accelerating the pace of drug discovery and development. This, in turn, leads to the introduction of new and improved therapies that address unmet medical needs and improve patient outcomes. Pharmaceutical CDMOs have become integral partners for pharmaceutical companies, offering a range of services including drug substance manufacturing, formulation development, and process optimization. By leveraging the expertise and capabilities of CDMOs, pharmaceutical companies can streamline their operations, reduce costs, and bring innovative products to market faster. The collaborative partnership between pharmaceutical companies and CDMOs is essential for driving positive growth in the healthcare industry and advancing the development of new therapies for patients worldwide.

Key Market Drivers

Increasing Demand for Customized Drug Development

Pharmaceutical companies often require specialized expertise and technologies to develop and manufacture customized drugs, which may include complex small molecules, biologics, high-potency compounds, or novel formulations. CDMOs with a focus on customization have the necessary knowledge and infrastructure to meet these specific needs, making them invaluable partners for pharmaceutical companies. Customized drug development often involves innovative and unique approaches to drug design and manufacturing. CDMOs can provide pharmaceutical companies with the resources and capabilities to expedite drug development processes, reducing time-to-market for new drugs.

Customized drug development can be resource-intensive, requiring substantial investments in research and development (R&D). Outsourcing to CDMOs allows pharmaceutical companies to access specialized capabilities without the need for substantial in-house investments, thereby reducing overall R&D costs. CDMOs offer scalable manufacturing solutions, allowing pharmaceutical companies to adjust production volumes as needed. This scalability is crucial for customized drugs, as demand can vary widely, from small-batch clinical trials to large-scale commercial production. Customized drug development often involves high levels of technical risk due to the unique nature of the compounds or formulations. By partnering with experienced CDMOs, pharmaceutical companies can mitigate these risks by leveraging the CDMO's expertise and track record in handling similar challenges. CDMOs specializing in customized drug development are well-versed in navigating complex regulatory requirements. They can help ensure that the customized drugs meet all regulatory standards, which is crucial for gaining approval and commercialization.

Growing Biopharmaceuticals Sector

Biopharmaceuticals, which include biologics like monoclonal antibodies, vaccines, and gene therapies, require specialized manufacturing processes. CDMOs with expertise in bioprocessing and biomanufacturing are in high demand to assist pharmaceutical companies in producing these complex and large-molecule drugs. Many pharmaceutical companies, especially smaller or newer entrants in the industry, may not have the in-house expertise or infrastructure for biologics development and manufacturing. They turn to CDMOs to access the necessary resources and skills. Building and maintaining biopharmaceutical manufacturing facilities can be incredibly expensive and time-consuming. Outsourcing to CDMOs allows pharmaceutical companies to reduce capital expenditures, minimize operational costs, and achieve cost-efficiency in biologics production.

The biopharmaceutical industry often faces fluctuations in demand, particularly for biologics with variable production requirements. CDMOs offer the flexibility to scale up or down production volumes as needed, optimizing resource utilization for pharmaceutical companies. Regulatory agencies have stringent requirements for the manufacturing and quality control of biologics. Established CDMOs have a track record of compliance with these regulations, giving pharmaceutical companies confidence in the quality and safety of their biopharmaceutical products. CDMOs specializing in biologics can expedite the drug development and manufacturing process. Their expertise, infrastructure, and streamlined operations can significantly reduce the time it takes to bring biopharmaceutical products to market, enabling pharmaceutical companies to capture opportunities more quickly.

Rise in Complex Drug Molecules

Complex drug molecules, which include high-potency APIs, biologics, and advanced formulations, require specialized knowledge and capabilities for their development and manufacturing. CDMOs with expertise in handling complex drug molecules become essential partners for pharmaceutical companies seeking to navigate the challenges of these compounds. Complex drug molecules often necessitate the use of advanced technologies and sophisticated manufacturing processes. CDMOs invest in state-of-the-art equipment and infrastructure to accommodate these requirements, making them well-suited to support the development and production of complex drugs. Developing and manufacturing complex drug molecules can be associated with higher technical and regulatory risks. Pharmaceutical companies can mitigate these risks by partnering with experienced CDMOs that have a proven track record of successfully handling complex compounds.

Complex drug molecules frequently face rigorous regulatory scrutiny due to their unique characteristics. CDMOs specializing in complex compounds have established quality assurance systems and compliance protocols to ensure that the products meet regulatory requirements. Developing and maintaining the infrastructure for complex drug manufacturing can be prohibitively expensive. By outsourcing to CDMOs, pharmaceutical companies can reduce capital investments, minimize operational costs, and achieve cost-efficiency in the production of complex drug molecules. CDMOs can tailor their services to the specific needs of pharmaceutical companies developing complex drugs. This customization ensures that the manufacturing processes are optimized for the unique properties and requirements of each compound.

Key Market Challenges

Regulatory Complexities

The pharmaceutical industry is highly regulated, and CDMOs must adhere to a myriad of stringent quality and safety standards. Compliance with these regulations often requires significant investments in infrastructure, personnel, and documentation. The associated compliance costs can reduce profit margins and make it challenging for CDMOs to offer competitive pricing. Regulatory approvals and compliance checks can introduce delays into the drug development and manufacturing process. CDMOs may face prolonged approval processes, inspections, and audits, which can impact project timelines. Pharmaceutical companies may seek faster alternatives, such as in-house manufacturing, to mitigate these delays. Meeting regulatory requirements demands substantial resources, including specialized personnel and extensive documentation. Smaller or newer CDMOs may struggle to allocate the necessary resources, hindering their ability to compete effectively in the market.

The pharmaceutical regulatory landscape varies from one region to another, with differences in standards, documentation, and inspection requirements. CDMOs operating in multiple countries must navigate this complex global regulatory environment, which can be both time-consuming and costly. Regulatory non-compliance can have severe consequences, including product recalls, legal penalties, and damage to a CDMO's reputation. The fear of non-compliance may deter pharmaceutical companies from partnering with CDMOs, especially those without a strong track record of regulatory adherence. Regulatory agencies demand extensive documentation of manufacturing processes, quality control, and product testing. Maintaining accurate and comprehensive records is resource-intensive and can divert CDMO staff from core activities.

Quality Control and Compliance

Ensuring quality and compliance requires significant investments in infrastructure, personnel, and quality control processes. CDMOs must allocate substantial resources to maintain compliance, which can increase operational costs and reduce profit margins. Quality assurance and compliance procedures often involve meticulous documentation, quality control checks, and validation processes. These activities can be time-consuming and may introduce delays into project timelines, potentially frustrating pharmaceutical clients. Regulatory authorities impose strict standards on the pharmaceutical industry to ensure product safety and efficacy. CDMOs must continuously monitor and adapt to these evolving regulations, which can be complex and demanding.

Non-compliance with quality and regulatory standards can have severe consequences, including product recalls, regulatory fines, and reputational damage. The fear of non-compliance can make pharmaceutical companies cautious about partnering with CDMOs that do not have a strong track record in this regard. Maintaining comprehensive documentation for every aspect of drug development and manufacturing is a fundamental requirement for compliance. The extensive paperwork and record-keeping can be resource-intensive and divert CDMO staff from core tasks. The global pharmaceutical market encompasses a range of regulatory bodies, each with its own set of requirements. CDMOs operating on a global scale must navigate the varying compliance standards of different regions, adding complexity to their operations.

Key Market Trends

Cell and Gene Therapies

Cell and gene therapies require highly specialized expertise and infrastructure for development and manufacturing. CDMOs with capabilities in cell culture, viral vector production, and gene editing technologies are in high demand to support these innovative therapies. CDMOs are investing heavily in cutting-edge technologies and facilities tailored for cell and gene therapy production. This includes state-of-the-art cleanroom environments, bioreactors, and cryopreservation systems designed to meet the unique requirements of these therapies. The growth in demand for cell and gene therapies has prompted CDMOs to expand their manufacturing capacity in this sector. This includes constructing dedicated facilities to handle the specialized processes involved in the production of these therapies.

The regulatory landscape for cell and gene therapies is complex and evolving. CDMOs specializing in these therapies possess in-depth knowledge of regulatory requirements, helping pharmaceutical companies navigate the approval process and ensure compliance. Cell and gene therapies come with inherent technical and regulatory risks. Pharmaceutical companies mitigate these risks by partnering with CDMOs experienced in managing the complexities and challenges associated with these therapies. The demand for cell and gene therapies extends worldwide, necessitating a global presence for CDMOs to provide access to diverse markets and ensure compliance with local regulatory authorities.

Segmental Insights

Synthesis Insights

Based on Synthesis, the biotech emerged as the fastest growing segment in the Global Active Pharmaceutical Ingredients CDMO Market in 2023. The biotech sector is increasingly focused on rare diseases, leading to a growing demand for CDMOs specializing in the development and manufacturing of orphan drugs. These drugs often require unique formulations and production processes. As research in neurodegenerative disorders like Alzheimer's and Parkinson's disease advances, CDMOs are providing support for the development of innovative therapies targeting these conditions. This segment is poised for growth as more therapies progress through clinical trials. The development of vaccines, antiviral drugs, and treatments for infectious diseases remains a critical area of biotech research. CDMOs are contributing to the manufacturing of vaccines and therapies for infectious diseases, particularly in response to global health crises like pandemics.

Drug Type Insights

Based on Drug Type, the generics emerged as the dominating segment in the Global Active Pharmaceutical Ingredients CDMO Market during forecast period. Generic drugs are typically produced at a lower cost compared to their branded counterparts. CDMOs specializing in generics can leverage efficient and cost-effective manufacturing processes to meet the high demand for these products. The rising demand for generic drugs, driven by the need for affordable healthcare solutions, presents growth opportunities for CDMOs. As pharmaceutical companies seek to expand their generic drug portfolios, they often turn to CDMOs to access cost-efficient manufacturing capabilities. Generic drugs encompass a wide range of therapeutic categories, including cardiovascular, central nervous system, and respiratory medications. This diversity offers CDMOs opportunities to work on a variety of drug formulations and compounds.

Some generic drugs, particularly complex generics such as biosimilars and specialty generics, require advanced manufacturing technologies and expertise. CDMOs with capabilities in bioprocessing, sterile manufacturing, and complex dosage forms are in demand to support the development and production of these products. Ensuring regulatory compliance is crucial in the generic drug industry. CDMOs with a strong track record of meeting regulatory standards and navigating the complexities of abbreviated new drug applications (ANDAs) are sought after by pharmaceutical companies. The global reach of generic drugs creates opportunities for CDMOs with a presence in multiple regions. These CDMOs can help pharmaceutical companies access diverse markets and meet local regulatory requirements.

Regional Insights

Based on region, North America dominated the Global Active Pharmaceutical Ingredients CDMO Market in 2023. This is primarily due to North America, particularly the United States, represents one of the largest pharmaceutical markets in the world. The region's prominence in pharmaceutical research, development, and manufacturing makes it a primary driver of global API CDMO market growth. Pharmaceutical companies in North America increasingly rely on CDMOs to outsource various stages of drug development and manufacturing. The growing demand for CDMO services is driven by factors such as cost-efficiency, regulatory expertise, and access to specialized technologies. North America is a global hub for biotechnology and pharmaceutical research and innovation. This concentration of biotech and pharma companies creates a thriving ecosystem for CDMOs to collaborate and provide essential support in developing novel drug compounds.

North America is a leader in the development of biologics and complex molecules, including monoclonal antibodies, gene therapies, and biosimilars. CDMOs with expertise in these areas are well-positioned to serve the region's biopharmaceutical companies. North America has stringent regulatory requirements for drug development and manufacturing. CDMOs operating in the region must maintain a deep understanding of regulatory standards and demonstrate compliance, making them valuable partners for pharmaceutical companies navigating this complex landscape. North American pharmaceutical companies often form strategic alliances with CDMOs to expedite drug development and access specialized expertise. These collaborations drive growth in the Active Pharmaceutical Ingredients CDMO market as they tap into the region's extensive pharmaceutical infrastructure.

Key Market Players

Cambrex Corporation

Thermo Fisher Scientific, Inc.

Recipharm AB

Corden Pharma International GmbH

Samsung Biologics Co., Ltd.

Lonza Group Ltd.

Siegfried Holding AG

Piramal Pharma Limited

AbbVie Inc.

Catalent, Inc.

Report Scope:

In this report, the Global Active Pharmaceutical Ingredients CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Active Pharmaceutical Ingredients CDMO Market, By Molecule Type:

    Small Molecule Large Molecule

Active Pharmaceutical Ingredients CDMO Market, By Synthesis:

    Biotech Synthetic

Active Pharmaceutical Ingredients CDMO Market, By Drug Type:

    Innovative Generics

Active Pharmaceutical Ingredients CDMO Market, By Workflow:

    Clinical Commercial

Active Pharmaceutical Ingredients CDMO Market, By Application:

    Cardiology Oncology Ophthalmology Neurology Orthopedic Other

Active Pharmaceutical Ingredients CDMO Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Active Pharmaceutical Ingredients CDMO Market.

Available Customizations:

Global Active Pharmaceutical Ingredients CDMO Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Active Pharmaceutical Ingredients CDMO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Molecule Type (Small Molecule, Large Molecule)
    • 5.2.2. By Synthesis (Biotech, Synthetic)
    • 5.2.3. By Drug Type (Innovative, Generics)
    • 5.2.4. By Workflow (Clinical, Commercial)
    • 5.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
    • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.7. By Company (2023)
  • 5.3. Market Map
  • 5.3.1 By Molecule Type
  • 5.3.2 By Synthesis
  • 5.3.3 By Drug Type
  • 5.3.4 By Workflow
  • 5.3.5 By Application
  • 5.3.6 By Region

6. North America Active Pharmaceutical Ingredients CDMO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Molecule Type (Small Molecule, Large Molecule)
    • 6.2.2. By Synthesis (Biotech, Synthetic)
    • 6.2.3. By Drug Type (Innovative, Generics)
    • 6.2.4. By Workflow (Clinical, Commercial)
    • 6.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Active Pharmaceutical Ingredients CDMO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Molecule Type
        • 6.3.1.2.2. By Synthesis
        • 6.3.1.2.3. By Drug Type
        • 6.3.1.2.4. By Workflow
        • 6.3.1.2.5. By Application
    • 6.3.2. Canada Active Pharmaceutical Ingredients CDMO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Molecule Type
        • 6.3.2.2.2. By Synthesis
        • 6.3.2.2.3. By Drug Type
        • 6.3.2.2.4. By Workflow
        • 6.3.2.2.5. By Application
    • 6.3.3. Mexico Active Pharmaceutical Ingredients CDMO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Molecule Type
        • 6.3.3.2.2. By Synthesis
        • 6.3.3.2.3. By Drug Type
        • 6.3.3.2.4. By Workflow
        • 6.3.3.2.5. By Application

7. Europe Active Pharmaceutical Ingredients CDMO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Molecule Type (Small Molecule, Large Molecule)
    • 7.2.2. By Synthesis (Biotech, Synthetic)
    • 7.2.3. By Drug Type (Innovative, Generics)
    • 7.2.4. By Workflow (Clinical, Commercial)
    • 7.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Molecule Type
        • 7.3.1.2.2. By Synthesis
        • 7.3.1.2.3. By Drug Type
        • 7.3.1.2.4. By Workflow
        • 7.3.1.2.5. By Application
    • 7.3.2. Germany Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Molecule Type
        • 7.3.2.2.2. By Synthesis
        • 7.3.2.2.3. By Drug Type
        • 7.3.2.2.4. By Workflow
        • 7.3.2.2.5. By Application
    • 7.3.3. United Kingdom Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Molecule Type
        • 7.3.3.2.2. By Synthesis
        • 7.3.3.2.3. By Drug Type
        • 7.3.3.2.4. By Workflow
        • 7.3.3.2.5. By Application
    • 7.3.4. Italy Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Molecule Type
        • 7.3.4.2.2. By Synthesis
        • 7.3.4.2.3. By Drug Type
        • 7.3.4.2.4. By Workflow
        • 7.3.4.2.5. By Application
    • 7.3.5. Spain Active Pharmaceutical Ingredients CDMO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Molecule Type
        • 7.3.5.2.2. By Synthesis
        • 7.3.5.2.3. By Drug Type
        • 7.3.5.2.4. By Workflow
        • 7.3.5.2.5. By Application

8. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Molecule Type (Small Molecule, Large Molecule)
    • 8.2.2. By Synthesis (Biotech, Synthetic)
    • 8.2.3. By Drug Type (Innovative, Generics)
    • 8.2.4. By Workflow (Clinical, Commercial)
    • 8.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Molecule Type
        • 8.3.1.2.2. By Synthesis
        • 8.3.1.2.3. By Drug Type
        • 8.3.1.2.4. By Workflow
        • 8.3.1.2.5. By Application
    • 8.3.2. India Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Molecule Type
        • 8.3.2.2.2. By Synthesis
        • 8.3.2.2.3. By Drug Type
        • 8.3.2.2.4. By Workflow
        • 8.3.2.2.5. By Application
    • 8.3.3. Japan Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Molecule Type
        • 8.3.3.2.2. By Synthesis
        • 8.3.3.2.3. By Drug Type
        • 8.3.3.2.4. By Workflow
        • 8.3.3.2.5. By Application
    • 8.3.4. South Korea Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Molecule Type
        • 8.3.4.2.2. By Synthesis
        • 8.3.4.2.3. By Drug Type
        • 8.3.4.2.4. By Workflow
        • 8.3.4.2.5. By Application
    • 8.3.5. Australia Active Pharmaceutical Ingredients CDMO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Molecule Type
        • 8.3.5.2.2. By Synthesis
        • 8.3.5.2.3. By Drug Type
        • 8.3.5.2.4. By Workflow
        • 8.3.5.2.5. By Application

9. South America Active Pharmaceutical Ingredients CDMO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Molecule Type (Small Molecule, Large Molecule)
    • 9.2.2. By Synthesis (Biotech, Synthetic)
    • 9.2.3. By Drug Type (Innovative, Generics)
    • 9.2.4. By Workflow (Clinical, Commercial)
    • 9.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Active Pharmaceutical Ingredients CDMO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Molecule Type
        • 9.3.1.2.2. By Synthesis
        • 9.3.1.2.3. By Drug Type
        • 9.3.1.2.4. By Workflow
        • 9.3.1.2.5. By Application
    • 9.3.2. Argentina Active Pharmaceutical Ingredients CDMO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Molecule Type
        • 9.3.2.2.2. By Synthesis
        • 9.3.2.2.3. By Drug Type
        • 9.3.2.2.4. By Workflow
        • 9.3.2.2.5. By Application
    • 9.3.3. Colombia Active Pharmaceutical Ingredients CDMO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Molecule Type
        • 9.3.3.2.2. By Synthesis
        • 9.3.3.2.3. By Drug Type
        • 9.3.3.2.4. By Workflow
        • 9.3.3.2.5. By Application

10. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Molecule Type (Small Molecule, Large Molecule)
    • 10.2.2. By Synthesis (Biotech, Synthetic)
    • 10.2.3. By Drug Type (Innovative, Generics)
    • 10.2.4. By Workflow (Clinical, Commercial)
    • 10.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Active Pharmaceutical Ingredients CDMO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Molecule Type
        • 10.3.1.2.2. By Synthesis
        • 10.3.1.2.3. By Drug Type
        • 10.3.1.2.4. By Workflow
        • 10.3.1.2.5. By Application
    • 10.3.2. Saudi Arabia Active Pharmaceutical Ingredients CDMO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Molecule Type
        • 10.3.2.2.2. By Synthesis
        • 10.3.2.2.3. By Drug Type
        • 10.3.2.2.4. By Workflow
        • 10.3.2.2.5. By Application
    • 10.3.3. UAE Active Pharmaceutical Ingredients CDMO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Molecule Type
        • 10.3.3.2.2. By Synthesis
        • 10.3.3.2.3. By Drug Type
        • 10.3.3.2.4. By Workflow
        • 10.3.3.2.5. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Active Pharmaceutical Ingredients CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Cambrex Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Key Personnel
    • 15.1.6. SWOT Analysis
  • 15.2. Thermo Fisher Scientific, Inc.
  • 15.3. Recipharm AB
  • 15.4. Corden Pharma International GmbH
  • 15.5. Samsung Biologics Co., Ltd.
  • 15.6. Lonza Group Ltd.
  • 15.7. Siegfried Holding AG
  • 15.8. Piramal Pharma Limited
  • 15.9. AbbVie Inc.
  • 15.10. Catalent, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제